Gcore Introduces AI-Driven Web Application and API Protection at the Edge
17.9.2024 10:00:00 CEST | Business Wire | Press release
Gcore WAAP delivers comprehensive web application and API protection against a broad range of advanced threats, including zero-day exploits, malicious bots, and application-layer DDoS attacks—all in one powerful solution.
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the launch of Gcore WAAP, its end-to-end web application and API protection solution. Leveraging advanced AI capabilities, Gcore WAAP integrates four powerful products in one solution: web application firewall (WAF), application-layer DDoS protection, bot management, and API security, all managed through an intuitive user interface. This comprehensive, multi-layered security solution protects digital assets across a wide range of verticals, including retail, financial services, healthcare, public sector, media and entertainment, and technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917971916/en/
Gcore WAAP delivers comprehensive web application and API protection against a broad range of advanced threats (Graphic: Business Wire)
Gcore WAAP was developed following the company’s acquisition of the StackPath WAAP solution earlier this year, now enhanced with AI-driven features and integrated into Gcore’s trusted global edge platform with 180+ points of presence. This cutting-edge WAAP solution provides comprehensive protection for websites, applications, and APIs against evolving threats while also helping businesses meet industry standards, such as GDPR, PCI DSS, and ISO 27001, supporting data sovereignty and regulatory compliance.
Enterprise-level threat mitigation at the edge
Gcore WAAP continuously monitors and analyses web application and API traffic at the edge, mitigating threats before they reach protected resources. It automatically scales to maintain consistent protection without compromising web performance. With AI-driven threat detection, behavioural analysis, and machine learning, WAAP uses insights from Gcore’s edge platform to identify patterns of malicious activity. The solution addresses evolving threats, quickly adapting to new vulnerabilities and attack patterns to keep defences robust and up to date.
“With the launch of Gcore WAAP, companies can now manage web application and API protection from a single platform, leveraging advanced AI-driven features, and at a price that makes top-tier protection accessible to all,” commented Andre Reitenbach, CEO at Gcore. “Security does not have to be complicated and, with Gcore WAAP at the edge, we’ve made it easier than ever for our customers to protect their businesses and customers, wherever they are in the world.”
Summary of key product capabilities
- Web application firewall (WAF): Delivers robust protection against OWASP Top 10 threats and zero-day attacks. Highly configurable with custom and advanced rules, heuristics, and behavioural analytics to detect and block malicious traffic before vulnerabilities are exploited. Includes device-level fingerprinting for enhanced security.
- L7 DDoS protection: Mitigates application-layer DDoS attacks of any size with adaptive and behavioural protection. Monitors both regular IP and API traffic, using AI-based IP filtering, rate limiting, browser validation, and classification features to neutralise malicious traffic and maintain the availability of web applications.
- Bot management: Distinguishes between legitimate users, good bots, and malicious bots to protect against automated attacks and fraud. Uses behavioural analytics, JavaScript challenges, CAPTCHA detection, session management, and browser validation to defend against threats like scraping, credential stuffing, and brute-force attacks.
- API security: Leverages WAF and DDoS mitigation features to defend against targeted threats for enterprise-grade API discovery and protection. Employs proprietary ML-based IP filtering, AI-driven profiling with JA3 fingerprints, and heuristics-based behaviour adjustment to provide adaptive, robust defence against API vulnerabilities.
Gcore WAAP is a cloud-based solution that can be implemented quickly and effortlessly. It is ideal for both security professionals and those without technical expertise, offering out-of-the-box functionality or customisable configurations to meet specific requirements. With competitive pricing starting at just €55 per month, Gcore WAAP makes robust web application and API protection accessible to businesses of all sizes.
Learn more about Gcore WAAP and sign up for a free trial by visiting https://gcore.com/web-app-and-api-protection.
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, with a team of 600 operating from ten offices worldwide, Gcore provides solutions to global leaders in numerous industries. Gcore manages its global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM due to the average response time of 30 ms worldwide. Gcore’s network consists of 180 points of presence worldwide in reliable Tier IV and Tier III data centers, with a total network capacity exceeding 200 Tbps. Learn more at gcore.com.
Website | Twitter | Facebook | LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917971916/en/
Contacts
Contact
Contact
pr@gcore.comAgency contacts
gcore@ascendcomms.net
Tel: +44 (0) 7956 955625 / +44 (0) 7719 863333
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom